Almirall Lowers Outlook

BMI's prediction that the Spanish government's austerity measures will have a big impact on local drugmaker Almirall has been reinforced - the pharmaceutical company has cut its 2010 guidance, expecting its revenues to fall by about 5%.[1] The Spanish drug market accounts for more than half of Almirall's sales and the company's revenue growth in the market had already slowed to 0.5% in Q110.

To read the full article, please choose one of the following options: